share_log

Wedbush Reiterates Outperform on Janux Therapeutics, Maintains $24 Price Target

Benzinga ·  Aug 10, 2023 09:42

Wedbush analyst Robert Driscoll reiterates Janux Therapeutics (NASDAQ:JANX) with a Outperform and maintains $24 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment